US-based medical device company Acelity has launched a new adjunctive non-surgical dressing, VAC Veraflo Cleanse Choice, that can be used to clean large complex wounds.
Combined with the firm’s negative pressure wound therapy and instillation (NPWTi-d) system called VAC Veraflo Therapy, the new dressing is expected to allow rapid cleansing when complete surgical debridement is not possible or appropriate.
The dressing comes with a three-layer foam design, enabling selective cleaning of affected tissue and infectious materials.
It features a contact layer designed to provide mechanical movement at the surface of the wound, as well as two cover layers that enable application on wounds with different depths.
Acelity president and chief executive officer Joe Woody said: “When considering treatment options for a severe wound, our aim is to provide clinicians and caregivers with greater certainty by offering the most robust and advanced portfolio of solutions that includes industry-leading therapies and the unique service offerings that only Acelity provides.”
A clinical study was conducted on 21 patients to investigate the efficacy of the dressing.
The results showed that the combined dressing and VAC Ulta Therapy solution was able to loosen, solubilise, separate and eliminate viscous wound exudate from the wound.
This was found to be similar in cases of cleansing with or without surgical intervention.
When used for a complete treatment period with routine dressing changes, the dressing minimised the surface area of black non-viable tissue and yellow fibrinous slough.
The VAC Veraflo Cleanse Choice dressing is currently available in the US, Canada, Europe and Latin America.